NCT00818779 is a Phase 4 clinical trial of Aliskiren in Coronary Artery Disease, sponsored by Texas Tech University Health Sciences Center.

Who is sponsoring NCT00818779?

NCT00818779 is sponsored by Texas Tech University Health Sciences Center.

What drugs are being tested in NCT00818779?

Interventions in NCT00818779: Aliskiren, Amlodipine.

What condition does NCT00818779 study?

NCT00818779 studies Coronary Artery Disease, Type 2 Diabetes Mellitus.

Is NCT00818779 still recruiting?

NCT00818779 is currently completed. Last updated 31 October 2017.

Are results published for NCT00818779?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-10-31 · How we verify

NCT00818779

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Heart Disease and Type 2 Diabetes Mellitus

Completed Phase 4 Results posted Last updated 31 October 2017

What this trial tests

Phase 4 trial testing Aliskiren in Coronary Artery Disease in 38 participants. Completed in 1 August 2011.

Timeline

1 January 2008

Primary endpoint
1 August 2011

1 August 2011

Quick facts

Lead sponsor	Texas Tech University Health Sciences Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	38
Start date	1 January 2008
Primary completion	1 August 2011
Estimated completion	1 August 2011
Sites	1 location across United States

Drugs / interventions tested

Aliskiren (ALISKIREN) — full drug profile →
Amlodipine (amlodipine) — full drug profile →

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Texas Tech University Health Sciences Center

Who can join

Adults 18 to 85, any sex, with Coronary Artery Disease or Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Plasminogen Activator Inhibitor 1
Time frame: 6 weeks (change from baseline)
Plasminogen Activator Inhibitor 1 is a biomarker found in serum that indirectly assesses blood clotting activity. Lower PAI-1 levels are thought to be better than higher levels. The primary outcome is mean change from baseline and can include negative numbers as a result.

Sponsor's own description

The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Aliskiren

Trials testing the same drug.

NCT06718062 — Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia · Phase 4 · completed
NCT00667719 — A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Ess · Phase 3 · completed

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Texas Tech University Health Sciences Center trials

Trials by the same sponsor.

NCT07348406 — Snacks and Brain Health · Phase 1, PHASE2 · not yet recruiting
NCT07407426 — EEG-Guided Binaural Beat Audio to Reduce Performance-Related Stress and Improve Cognition · NA · not yet recruiting
NCT07434375 — Speech Intervention Via Telepractice for Children With Repaired Cleft Palate · NA · not yet recruiting
NCT07451210 — Evaluating the Efficacy of Blood Flow Restriction Therapy in a Randomized Clinical Trial for Postoperative Rehabilitatio · NA · recruiting
NCT07309874 — Effect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00818779 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Texas Tech University Health Sciences Center
Last refreshed: 31 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00818779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing